JP2014532722A5 - - Google Patents

Download PDF

Info

Publication number
JP2014532722A5
JP2014532722A5 JP2014540139A JP2014540139A JP2014532722A5 JP 2014532722 A5 JP2014532722 A5 JP 2014532722A5 JP 2014540139 A JP2014540139 A JP 2014540139A JP 2014540139 A JP2014540139 A JP 2014540139A JP 2014532722 A5 JP2014532722 A5 JP 2014532722A5
Authority
JP
Japan
Prior art keywords
peptide
use according
formulated
administration
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014540139A
Other languages
English (en)
Japanese (ja)
Other versions
JP6170933B2 (ja
JP2014532722A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/063332 external-priority patent/WO2013067357A1/en
Publication of JP2014532722A publication Critical patent/JP2014532722A/ja
Publication of JP2014532722A5 publication Critical patent/JP2014532722A5/ja
Application granted granted Critical
Publication of JP6170933B2 publication Critical patent/JP6170933B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014540139A 2011-11-02 2012-11-02 ペプチドの使用 Expired - Fee Related JP6170933B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161554771P 2011-11-02 2011-11-02
US61/554,771 2011-11-02
US201161578620P 2011-12-21 2011-12-21
US61/578,620 2011-12-21
US13/667,578 2012-11-02
PCT/US2012/063332 WO2013067357A1 (en) 2011-11-02 2012-11-02 Peptide analogs for treating diseases and disorders
US13/667,578 US9006172B2 (en) 2011-11-02 2012-11-02 Peptide analogs for treating diseases and disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016216389A Division JP6330013B2 (ja) 2011-11-02 2016-11-04 疾患および障害を処置するためのペプチド類似体

Publications (3)

Publication Number Publication Date
JP2014532722A JP2014532722A (ja) 2014-12-08
JP2014532722A5 true JP2014532722A5 (enExample) 2015-11-26
JP6170933B2 JP6170933B2 (ja) 2017-07-26

Family

ID=48192827

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014540139A Expired - Fee Related JP6170933B2 (ja) 2011-11-02 2012-11-02 ペプチドの使用
JP2016216389A Expired - Fee Related JP6330013B2 (ja) 2011-11-02 2016-11-04 疾患および障害を処置するためのペプチド類似体
JP2018081153A Expired - Fee Related JP6547034B2 (ja) 2011-11-02 2018-04-20 ペプチドの使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2016216389A Expired - Fee Related JP6330013B2 (ja) 2011-11-02 2016-11-04 疾患および障害を処置するためのペプチド類似体
JP2018081153A Expired - Fee Related JP6547034B2 (ja) 2011-11-02 2018-04-20 ペプチドの使用

Country Status (10)

Country Link
US (1) US9006172B2 (enExample)
JP (3) JP6170933B2 (enExample)
KR (1) KR102019911B1 (enExample)
CN (1) CN103998052B (enExample)
AU (2) AU2012332265B2 (enExample)
BR (1) BR112014010701A2 (enExample)
CA (1) CA2854175A1 (enExample)
MX (1) MX351092B (enExample)
RU (1) RU2616511C2 (enExample)
WO (1) WO2013067357A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9533022B2 (en) * 2011-11-02 2017-01-03 KeyBioscience A/S Peptide analogs for treating diseases and disorders
HUE037663T2 (hu) * 2013-11-14 2018-09-28 Keybioscience Ag Kalcitonin mimetikumok betegségek és rendellenességek kezelésére
GB201500263D0 (en) 2015-01-08 2015-02-25 Keybioscience Ag Calcitonin analogues for treating diseases and disorders
GB201704429D0 (en) 2017-03-21 2017-05-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
GB201707955D0 (en) 2017-05-18 2017-07-05 Keybioscience Ag Dual amylin and calcitonin receptor agonists for treating diseases and disorders
GB201813677D0 (en) 2018-08-22 2018-10-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
GB201813678D0 (en) 2018-08-22 2018-10-03 Keybioscience Ag Acylated calcitonin mimetics
US11420525B2 (en) 2020-04-21 2022-08-23 Mac LTT, Inc. Tractor trailer with included battery charging
US11634095B2 (en) 2020-04-21 2023-04-25 Mac LTT, Inc. Removable safety bar for creating a remote safety visual device
US12415457B2 (en) 2020-04-21 2025-09-16 Mac LTT, Inc. Safety zone with breakaway for use on a tanker truck

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6033478B2 (ja) * 1980-06-20 1985-08-02 帝国臓器製薬株式会社 ペプチドの製造方法
US4708934A (en) 1984-09-27 1987-11-24 Unigene Laboratories, Inc. α-amidation enzyme
US6319685B1 (en) 1984-09-27 2001-11-20 Unigene Laboratories, Inc. Alpha-amidating enzyme compositions and processes for their production and use
US4659804A (en) * 1984-11-01 1987-04-21 Armour Pharmaceutical Company (Bis-1,7-S-acetamidomethyl-L-cysteine)salmon calcitonin
US4764589A (en) 1987-05-26 1988-08-16 Rorer Pharmaceutical Corporation [N-alpha-acyl,8-glycine, des-19-leucine]-calcitonin
US5789234A (en) 1987-08-14 1998-08-04 Unigene Laboratories, Inc. Expression systems for amidating enzyme
US5175146A (en) 1989-12-05 1992-12-29 Vical, Inc. Synthetic calcitonin peptides
US5102666A (en) 1990-09-11 1992-04-07 Oramed, Inc. Calcium polycarbophil controlled release composition and method
US5527790A (en) 1991-09-30 1996-06-18 The University Of British Columbia Bis(maltolato)oxovanadium compositions for the treatment of elevated blood sugar
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US6692766B1 (en) 1994-06-15 2004-02-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Controlled release oral drug delivery system
JPH083196A (ja) 1994-06-21 1996-01-09 Sanwa Kagaku Kenkyusho Co Ltd カルシトニン誘導体及びその用途
DE726075T1 (de) 1995-02-08 1996-12-12 Therapicon Srl Nicht-inorganische pharmazeutische salzige Lösungen zur endonasale Verabreichung
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5739106A (en) 1995-06-07 1998-04-14 Rink; Timothy J. Appetite regulating compositions
CA2502764A1 (en) 1995-08-22 1997-03-06 Japan Tobacco Inc. Amide compounds
US5962270A (en) * 1996-02-06 1999-10-05 Bionebraska, Inc. Recombinant preparation of calcitonin fragments and use thereof in the preparation of calcitonin and related analogs
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US5773647A (en) 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
HUP0001272A3 (en) 1997-04-16 2012-12-28 Unigene Lab Inc Direct expression of peptides into culture media
CN1105726C (zh) * 1998-05-15 2003-04-16 中国科学院上海生物化学研究所 人降钙素类似物
AU1574900A (en) 1998-12-04 2000-06-26 Provalis (Uk) Limited Pharmaceutical compositions containing insulin
JP2000290295A (ja) 1999-03-31 2000-10-17 Asahi Chem Ind Co Ltd Ｎ−アセチルグルコサミニルカルシトニン
IL145546A0 (en) * 1999-04-05 2002-06-30 Emisphere Tech Inc Disodium salts, monohydrates, and ethanol solvates for delivering active agents
US6780846B1 (en) 1999-09-27 2004-08-24 Elan Corporation, Plc Membrane translocating peptide drug delivery system
GB2368792A (en) 2000-10-06 2002-05-15 Roger Randal Charles New Absorption enhancers
US6673574B2 (en) 2000-11-30 2004-01-06 Unigene Laboratories Inc. Oral delivery of peptides using enzyme-cleavable membrane translocators
US7316819B2 (en) 2001-03-08 2008-01-08 Unigene Laboratories, Inc. Oral peptide pharmaceutical dosage form and method of production
GB0109438D0 (en) * 2001-04-17 2001-06-06 Isis Innovation Peptides
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
ES2665464T3 (es) 2003-03-28 2018-04-25 Sigmoid Pharma Limited Forma de dosificación oral sólida que contiene microcápsulas sin costuras
GB0308732D0 (en) 2003-04-15 2003-05-21 Axcess Ltd Absorption enhancers
US7749954B2 (en) 2003-07-23 2010-07-06 Novartis Ag Use of calcitonin in osteoarthritis
US20070172517A1 (en) 2003-09-17 2007-07-26 Ben-Sasson Shmuel A Compositions capable of facilitation penetration across a biological barrier
AU2005320351B2 (en) 2004-02-11 2010-06-03 Amylin Pharmaceuticals, Llc Amylin family peptides and methods for making and using them
US7399744B2 (en) 2004-03-04 2008-07-15 Amylin Pharmaceuticals, Inc. Methods for affecting body composition
AU2005263729B2 (en) 2004-07-22 2011-01-06 Bey Pharma GmbH Use of compounds containing thiol groups as an efflux pump inhibitor
GB0422644D0 (en) * 2004-10-12 2004-11-10 Novartis Ag Organic compounds
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
US7445911B2 (en) 2004-11-24 2008-11-04 Unigene Laboratories Inc. Enzymatic reactions in the presence of keto acids
JP4856177B2 (ja) 2005-06-24 2012-01-18 ユニジーン・ラボラトリーズ・インコーポレーテッド アミド化生成物の調製に有用な酵素を発現させるための細胞株
EP2722054B1 (en) 2005-09-06 2018-03-21 Oramed Pharmaceuticals Inc. Methods and compositions for oral administration of proteins
US8093207B2 (en) 2005-12-09 2012-01-10 Unigene Laboratories, Inc. Fast-acting oral peptide pharmaceutical products
ES2369244T3 (es) 2006-03-13 2011-11-28 Advancell Advanced In Vitro Cell Technologies,S.A. Sistemas estables de nanocápsulas para la administración de moléculas activas.
AU2007235251B2 (en) 2006-04-07 2013-02-07 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US8377863B2 (en) 2007-05-29 2013-02-19 Unigene Laboratories Inc. Peptide pharmaceutical for oral delivery
US8962015B2 (en) 2007-09-28 2015-02-24 Sdg, Inc. Orally bioavailable lipid-based constructs
EP2389388B1 (en) * 2009-01-22 2017-03-08 KeyBioscience AG Treatment for obesity
RU2537181C2 (ru) * 2009-03-12 2014-12-27 Нордик Байосайенс А/С Лечение диабета и метаболического синдрома

Similar Documents

Publication Publication Date Title
JP2014532722A5 (enExample)
JP2012136541A5 (enExample)
JP2012126742A5 (enExample)
JP2014530220A5 (enExample)
JP2013507439A5 (enExample)
JP2013509429A5 (enExample)
JP2012041342A5 (enExample)
SI2709613T1 (en) Procedures for the treatment of HCV
RU2600440C3 (ru) Твердые композиции, содержащие агонист glp-1 и соль n-(8-(2-гидроксибензоил)амино)каприловой кислоты
JP2015518818A5 (enExample)
JP2011528896A5 (enExample)
JP2014503593A5 (enExample)
JP2011225596A5 (enExample)
JP2012512907A5 (enExample)
JP2015517488A5 (enExample)
JP2013067645A5 (enExample)
JP2012255026A5 (enExample)
JP2013231081A5 (enExample)
JP2010280671A5 (enExample)
NZ702801A (en) Treatment of sanfilippo syndrome type b
JP2014501492A5 (enExample)
NZ608502A (en) Polypeptides that bind to human complement component c5
RU2014122171A (ru) Пептидные аналоги для лечения заболеваний и расстройств
JP2011528897A5 (enExample)
JP2013047268A5 (enExample)